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http://dx.doi.org/10Arginine methylation is an abundant covalent modification that regulates diverse cellular pro-
cesses, including transcription, translation, DNA repair, and RNA processing. The enzymes
that catalyze these marks are known as the protein arginine methyltransferases (PRMTs),
and they can generate asymmetric dimethyl arginine (type I arginine methyltransferases),
symmetric dimethylarginine (type II arginine methyltransferases), or monomethyarginine
(type III arginine methyltransferases). The PRMTs are capable of modifying diverse sub-
strates, from histone components to specific nuclear and cytoplasmic proteins. Additionally,
the PRMTs can orchestrate chromatin remodeling by blocking the docking of other epigenetic
modifying enzymes or by recruiting them to specific gene loci. In the hematopoietic system,
PRMTs can regulate cell behavior, including the critical balance between stem cell self-
renewal and differentiation, in at least two critical ways, via (i) the covalent modification of
transcription factors and (ii) the regulation of histone modifications at promoters critical to
cell fate determination. Given these important functions, it is not surprising that these pro-
cesses are altered in hematopoietic malignancies, such as acute myeloid leukemia, where
they promote increased self-renewal and impair hematopoietic stem and progenitor cell dif-
ferentiation.  2016 ISEH - International Society for Experimental Hematology. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Recent advances in proteomics and mass spectroscopy have
made it possible to study how overall arginine methylation
levels change over time as hematopoietic cells differentiate.
In one study, primary T-lymphocytes and cell lines were
labeled using a methyl-SILAC approach, and the methyl-
ated peptides were subjected to mass spectrometry analysis
[1]. This analysis identified novel arginine methylated sub-
strates as well as how methylation events change in
response to extracellular stimuli (e.g., stimulation of T-cells
with CD3, CD28, and interleukin-2). The novel substrates
included transcription factors critical for T-cell maturation
as well as chromatin-modifying enzymes. These studies
clearly indicate that arginine methylation is a dynamically
regulated covalent modification in hematopoietic cells. In: Stephen D. Nimer, Sylvester Comprehensive Can-
Research Building, 1120 Northwest 14th Street
ite 660, Miami, FL 33136-1000; E-mail: SNimer@
EH - International Society for Experimental Hematology. P
//creativecommons.org/licenses/by-nc-nd/4.0/).
.1016/j.exphem.2016.03.009addition, accumulating evidence suggests that arginine
methylation can be a driving force in the initiation and pro-
gression of cancer. In this review, we describe in detail
those PRMTs with established roles in normal and malig-
nant hematopoiesis: PRMT1, PRMT4, PRMT5, PRMT6,
and PRMT7. The known associations between PRMT
expression and hematologic malignancies are summarized
in Table 1.PRMT1
PRMT1 is the predominant asymmetric (type I) methyl-
transferase in mammalian cells, and knockout of Prmt1 in
mice results in embryonic lethality at embryonic day 7.5,
with a two-fold reduction in total asymmetric arginine
methyltransferase activity [10,11]. Both histone and
nonhistone substrates of PRMT1 have been identified in
hematopoietic cells. Knockdown of PRMT1 through
siRNA-mediated depletion decreased levels of theublished by Elsevier Inc. This is an open access article under the CC BY-
Table 1. Non-histone targets of PRMTs and association with
hematologic malignancy
PRMT Key nonhistone proteins targets
Hematologic
malignancies
PRMT1 RUNX1, MLL complex, 53BP1,
SAM68, SWI/SNF
AML [2]
ALL [3]
Lymphoma [4,5]
PRMT4 RUNX1, MLL complex, SWI/SNF,
Sm proteins
AML [6]
Lymphoma [4,7]
PRMT5 SIN3A/HDAC1, P53, SWI/SNF, E2F,
Sm proteins
AML [8]
Mantle cell
lymphoma [9]
PRMT6 MLL complex, SIN3A/HDAC1, P53 Lymphoma [5]
PRMT7 MLL complex, Sm proteins Unknown
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repressive H3K9me and H3K27me marks at the b-globin
locus in erythrocytes [12]. The data suggest that PRMT1
promotes an active chromatin state at critical promoters
during hematopoietic cell differentiation, as H4R3 methyl-
ation by PRMT1 appears to increase the recruitment of the
acetyltransferase p300 to histone tails [13]. The ability of
the arginine methyltransferases to both directly modify his-
tones and indirectly promote or diminish other histone
modifications may explain how changes in PRMT protein
expression can have a widespread influence on transcrip-
tion. The direct and indirect effects of the PRMTs on his-
tone modifications are summarized in Table 2.
PRMT1 can regulate hematopoietic differentiation
through the arginine methylation of RUNX1, a transcription
factor critical for definitive hematopoiesis, myeloid differ-
entiation, and lymphocyte development (Fig. 1). Methyl-
ation of R206 and R210 by PRMT1 on the C-terminus of
RUNX1 impairs its association with the SIN3A co-
repressor, which increases the transcriptional activity of
the CD41 promoter, a RUNX1 target that is expressed by
primitive multipotent progenitor cells and megakaryocytes
[14]. Thus, in this context, PRMT1 appears to regulate tran-Table 2. Histone modifications and chromatin remodeling by the
PRMTs
Arginine
methyltransferase
Direct histone
modifications
Indirect effects on
histone modifications
PRMT1 H4R3 Impaired H3K9me
and H3K27me
PRMT4 H3R17 and H3R26 Recruitment of p300
to H3, increased
histone acetylation
PRMT5 H2A/H4R3 and H3R8 Impaired H3K9ac
PRMT6 H3R2 and H2AR29 Impaired binding of
MLL methyltransferase
complex to H3,
decreased H3K4me
PRMT7 H4R3 and H3R2 Impaired H3K4me
by MLL4scriptional activation during the normal maturation of the
myeloid and erythroid lineages. To determine the biological
significance of R206 and R210 methylation, knock-in
mouse strains were established, where the arginine residues
in RUNX1 were mutated to lysine (from RTAMR to
KTAMK) and, thus, were not subject to arginine
methylation [15]. Homozygous Runx1KTAMK/KTAMK mice
are viable, but exhibit defects in CD3þ T-lymphoid cells
and CD4þ T-cells in the peripheral lymphoid organs. These
findings suggest that methylation of RUNX1 by PRMT1 on
these sites is critical for proper peripheral T-cell
maintenance.
PRMT1 plays important roles in the context of acute
myeloid leukemia (AML) and acute lymphoblastic leuke-
mia (ALL). PRMT1 is significantly upregulated in newly
diagnosed patients with pediatric ALL [3]. The t(8:21)
translocation, which occurs in 10% of de novo AML, gen-
erates the AML1–ETO fusion protein, which interacts with
PRMT1. AML1–ETO has been characterized as both a
transcriptional activator and a repressor. Knockdown of
PRMT1 reduces the transcriptional activation of target
genes activated by AML1–ETO, decreasing proliferation
and inhibiting self-renewal [2]. PRMT1 is also found in
transcriptional regulatory complexes with mixed lineage
leukemia (MLL) fusion proteins, such as MLL-EEN.
Together, MLL–EEN and PRMT1 promote H4R3 arginine
methylation and expression from the HoxA9 promoter [16].
Interactions of MLL–EEN with PRMT1, or the PRMT1-
interacting protein Sam68, enhance hematopoietic cell
self-renewal. Conversely, knockdown of PRMT1 inhibits
leukemia transformation. More recently, PRMT1 has been
found to be required for leukemia induction by the leuke-
mia fusion proteins MLL–GAS7 and MOZ–TIF2 in mice
[17]. Although PRMT1 is overexpressed in Hodgkin’s lym-
phoma (HL) cell lines and primary lymphoid tissue, the sig-
nificance of PRMT1 in HL pathogenesis is unknown [4].
The regulation of splicing by the PRMTs is another
example of a process in which changes in PRMT expression
or activity can contribute to the initiation or maintenance of
hematologic malignancies. The spliceosome is a multipro-
tein complex containing small nuclear ribonucleic proteins,
and components of this complex are subject to mutations in
50% of patients with myelodysplastic syndrome [18]. Spe-
cific RNA-binding proteins are recognized as targets of
PRMT1, including RBM15, a protein that recruits the
splicing factor SF3B1 to intronic regions of genes that
are critical for megakaryocytic development (such as
GATA1 and RUNX1) [19]. Methylation of RBM15 (a
gene involved in an acute megakaryocytic leukemia-
associated translocation) decreases RBM15 protein levels
by triggering ubiquitin–proteosome-mediated degradation.
Ultimately, this leads to inhibition of megakaryocytic dif-
ferentiation. In summary, accumulating evidence suggests
that small molecule inhibitors of PRMT1 may exhibit effi-
cacy in AML, ALL, and HL.
Figure 1. Diagram of the RUNX1 protein and sites of regulation by the PRMT family. The RUNX1 transcription factor is directly modified by PRMT1 on
R206 and R210, which prevents its association with the SIN3A co-repressor and promotes its transcriptional activity. PRMT4 can directly modify RUNX1 on
R223, which triggers the formation of a repressive complex at RUNX1 target genes, such as mir223. PRMT6 and RUNX1 are also found in a co-repressor
complex containing SIN3A and HDAC1 in human CD34þ cells; however, this interaction (between RUNX1 and PRMT6) is lost following megakaryocytic
differentiation.
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PRMT4 was first identified as a transcriptional activator; it
methylates histone H3 at the unique sites H3R17 and
H3R26 and methylates many nonhistone substrates.
PRMT4 knockout mice are born, but they die shortly after
birth from defects in the differentiation of the lung paren-
chyma, adipocytes, and muscle cells [20]. T-cell differentia-
tion is also highly dependent on PRMT4 expression, as
PRMT null embryos exhibit severe defects in thymocyte pro-
genitor maturation [21]. PRMT4 has also been found to regu-
late cell fate decisions at the earliest stage of embryogenesis
[22]. The blastomere inner cell mass expresses high levels of
PRMT4, which positively regulate the expression of key plu-
ripotency genes, including Nanog and Sox2. PRMT4 deple-
tion downregulates these pluripotency genes, leading to
embryonic stem cell differentiation [23]. PRMT4 also mod-
ifies nonhistone substrates, such as MLL1/2, modulating its
binding to specific promoters during differentiation [24].
PRMT4 methylates other transcriptional co-activators such
as the steroid receptor co-activator AIB1 [25]. It has also
been implicated in the regulation of splicing through the post-
translational modification of multiple splicing factors,
including CA150, SAP49, SmB, and U1C [26]. In general,
methylation of these splicing factors by PRMT4 promotes
alternative splicing through exon skipping.
Our lab recently reported that PRMT4 is overexpressed
in patient AML samples and that PRMT4 negatively regu-
lates myeloid differentiation [6]. PRMT4 levels are highest
in undifferentiated human CD34þ cells, with decreased
expression as cells undergo cytokine-driven myeloid differ-
entiation in vitro. Furthermore, overexpression of PRMT4
blocks the myeloid differentiation of human HSPCs,
whereas its knockdown induces their myeloid differentia-
tion. Our lab identified a feedback loop, whereby PRMT4
modifies RUNX1 on arginine 223, leading to the recruit-
ment of a DPF2-containing repressor complex. Depletion
of PRMT4 (or DPF2) results in differentiation of myeloidleukemia cells in vitro and their decreased proliferation
in vivo, suggesting that targeting PRMT4 may be an effec-
tive therapeutic strategy for AML.
PRMT4 has also been implicated in modulating the activ-
ity of the SWI/SNF (BAF) chromatin-remodeling complex,
one of the most commonly mutated protein complexes in
cancer. SWI/SNF complexes control the transcriptional regu-
lation of genes involved in differentiation and cell prolifera-
tion, andBAF155/SMARCC1, a core component of the SWI/
SNF complex, is a substrate of PRMT4 [27]. Methylation of
BAF155 onR1064 affects the targeting of the SWI/SNFcom-
plex and upregulation of the c-Myc pathway. Overexpression
of PRMT4 and increased BAF155 methylation were both
seen in breast cancer samples obtained from patients with
the poorest survival outcomes. The regulation of SWI/SNF
complexes by PRMT4 does not appear to be limited to solid
tumors. Methylation of the transcription factor CEBPB or
RUNX1 by PRMT4 interferes with their binding to compo-
nents of the SWI/SNF complex [6,28]. In summary,
PRMT4may be an important regulator of SWI/SNF targeting
and transcriptional regulation in a variety of cancer cells.PRMT5
PRMT5 was originally identified as a JAK kinase-binding
protein in yeast two-hybrid assays; it was later found to
possess methyltransferase activity toward arginine residues
[29,30]. We now know that PRMT5 is the major type II
enzyme in mammalian cells, catalyzing the symmetric di-
methylation of arginine residues in histone (at H2A/H4R3
and H3R8) and numerous nonhistone proteins, including
MBD2, p53, HOXA9, and Sm Ribonucleoproteins
[31–34]. PRMT5-mediated methylation of histones is
generally thought to repress gene transcription; indeed,
PRMT5 is found in association with multiple co-repressor
complexes, including SIN3A/HDAC and MBD2/NuRD
[35]. PRMT5 also regulates RNA splicing by methylating
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facilitating biogenesis of the spliceosome [36,37]. Loss of
PRMT5 has been reported to affect splicing of numerous
genes in neural stem/progenitor cells, including MDM4, a
negative regulator of p53 [38,39]. In addition to transcrip-
tion regulation and RNA splicing, PRMT5 regulates many
other cellular processes, including signal transduction and
cell cycle progression [12,40].
PRMT5 functions in the context of several multimeric
complexes, which invariably contain the WD40-repeat pro-
tein MEP50, but also specific nuclear and cytoplasmic com-
ponents [41]. MEP50 is indispensable for PRMT5
enzymatic activity, whereas these other components regu-
late PRMT5 localization and substrate specificity. In the
cytoplasm, the PRMT5/MEP50 core complex interacts
with pICln or RioK1, which directs PRMT5 methyltransfer-
ase activity toward Sm proteins or nucleolin, respectively
[34,42]. In the nucleus, the core PRMT5 complex interacts
with COPR5 (coordinator of PRMT5), which promotes the
methylation of H4R3 by PRMT5, but also inhibits the abil-
ity of PRMT5 to methylate H3 at R8 [43]. The formation of
PRMT5 complexes can be regulated by upstream signaling
pathways. For example, our lab has previously found that
the myeloproliferative neoplasm-associated mutant JAK2
kinase (JAK2V617F) gains the ability to phosphorylate
PRMT5 and disrupt the interaction between PRMT5 and
MEP50, thus inhibiting PRMT5 methyltransferase activity
[44]. PRMT5 function is also regulated by its subcellular
localization, with cytoplasmic and nuclear PRMT5 having
distinct effects on stem cell development and possibly can-
cer cell proliferation [45]. How cells control the transloca-
tion of PRMT5 between the cytoplasm and the nucleus is
poorly understood.
PRMT5 has been reported to play an important role in
maintaining the pluripotency of both embryonic and adult
stem cells by inhibiting the expression of differentiation-
associated genes [46,47]. To study the function of PRMT5
in hematopoietic stem cells (HSCs), our lab generated an
inducible PRMT5 conditional knockout mouse. We deleted
PRMT5 in the hematopoietic cells of 2-month-old mice
and triggered a rapidly fatal bone marrow aplasia. We
observed a cell-intrinsic, nonhomeostatic transient expan-
sion of PRMT5-null HSCs, which identified a role for
PRMT5 in maintaining stem cell quiescence. However, the
exhaustion of both HSCs and hematopoietic progenitor cells
(HPCs) in PRMT5-null mice indicated the indispensable role
of this methyltransferase in maintaining normal HSPC func-
tion. We have completed several mechanistic studies to date
that identified severely impaired cytokine signaling and over-
active p53 signaling in PRMT5-deficient HSPCs, which may
explain some of the phenotypes we observed [48].
Growing evidence suggests that PRMT5 is involved in
tumorigenesis. Although recurrent mutations of PRMT5
are rarely observed in cancer cells, its expression level is
upregulated in leukemia, lymphoma, and many solid tu-mors [8,9,49]. PRMT5 is required for tumor cell prolifera-
tion, and overexpression of PRMT5 transforms cells [50].
The oncogenic role of PRMT5 in lymphomagenesis has
been extensively studied; elevated levels of PRMT5 protein
are found in primary lymphoma samples and cell lines,
leading to repression of the tumor suppressor RB proteins
(RB1, RBL1, and RBL2) [8]. PRMT5 upregulation is
induced by the ectopic expression of several oncogenes,
including Notch1, MLL-AF9, and Myc, and PRMT5 has
been reported to cooperate with mutant cyclin D
(D1T286A) to induce lymphomagenesis in mice [51].
Treating mantle cell lymphoma cells with PRMT5-
specific inhibitors exhibited promising in vitro and in vivo
anti-tumor efficacy [52]. The role of PRMT5 in the myeloid
malignancies is still under investigation. Although we have
found that loss of PRMT5 in normal HSPCs leads to
reduced cell surface expression of FLT3 (Fms-related Tyro-
sine Kinase 3), perhaps via the aberrant splicing of Flt3 pre-
mRNA, a recent report suggested that PRMT5 inhibition
reduces FLT3 levels via effects on mir-29b expression in
AML cells [53]. Given the high frequency of FLT3 muta-
tions in AML, PRMT5 could be a potential target for this
subset of myeloid malignancies. Several recent reports
have also described how deletion of MTAP, a gene that en-
codes an enzyme critical for methionine metabolism, may
sensitize cells to PRMT5 inhibition [54,55]. Because of
its proximity to the tumor suppressor gene CDKN2A on
9p21, MTAP is deleted in several solid tumor types as
well as diffuse B-cell lymphoma. MTAP-deficient cancer
cells accumulate a metabolite (MTA) that inhibits
PRMT5 activity, thus sensitizing them to further PRMT5
inhibition. These reports suggest that the subgroup of can-
cer patients with MTAP deletion may be ideal candidates
for treatment with PRMT5 inhibitors.PRMT6
PRMT6 is a type I arginine methyltransferase that is gener-
ally thought to methylate histone H3R2, a histone modifica-
tion that is associated with decreased levels of the
transcriptional activation mark H3K4me [56–59]. The
global distribution of H3R2me2a was mapped by character-
izing the regulatory regions of 200 genes in leukemia and
lymphoma cell lines. Interestingly, H3R2me2a was found
primarily at inactive promoters. Although H3R2me2a was
also localized in gene bodies, this had no correlation with
gene expression.
These studies also indicated that the antagonist relation-
ship between the methylation of H3R2 and H3K4 is recip-
rocal. The presence of H3K4 methylation on H3 peptides
prevented the ability of PRMT6 to methylate H3R2.
Conversely, the presence of H3R2me2a interfered with
recognition of the H3 tail by WDR5, a component of the
MLL methyltransferase complex that is necessary for the
bridging of the MLL methyltransferase and H3 [56,57].
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plexes, preventing the deposition of the H3K4 methylation
mark on promoter regions. In support of this hypothesis,
overexpression of PRMT6 was found to inhibit the recruit-
ment of the MLL methyltransferase complex to H3K4, and
it resulted in the decreased transcription of Hox- and Myc-
dependent genes. This process may be critical in regulating
embryonic stem cell differentiation and self-renewal, as
PRMT6 protein levels and H3R2 methylation levels in-
crease with the differentiation of mouse embryonic stem
cells, coinciding with decreased expression of genes regu-
lating pluripotency and self-renewal [59].
PRMT6 can also regulate lineage commitment at later
stages of hematopoietic differentiation through the modifi-
cation of RUNX1 function. Before megakaryocytic differen-
tiation, RUNX1 and PRMT6 are co-localized within a co-
repressor complex containing SIN3A and HDAC1, which
can be found at the promoters of megakaryocytic genes
such as CD41 [60,61]. These genes exhibit increased
expression of H3R2me and decreased H3K4me. However,
after megakaryocytic differentiation, RUNX1 is found in a
co-activator complex that lacks PRMT6 but contains p300
and WDR5. Decreased interaction with PRMT6 appears to
enhance the ability of RUNX1 to bind DNA on the regula-
tory regions of genes such as PU.1. The mechanism that reg-
ulates the recruitment or exclusion of PRMT6 at these
regulatory regions is still unknown, but may be related to
other posttranslational modifications of RUNX1.
Although PRMT6 null mice are viable, mouse embryo
fibroblasts from these mice display increased cellular senes-
cence because of high levels of p53 [62]. PRMT6 and
H3R2me2a were found to be enriched in an upstream reg-
ulatory region that controls p53 expression by chromatin
immunoprecipitation. PRMT6 has also been reported to
directly repress the cyclin-dependent kinase p21 promoter
in breast cancer cells [63]. This suggests that PRMT6-
mediated repression of p53 and p21 may be a critical func-
tion of this enzyme, and it supports the hypothesis that
PRMT6 functions as an oncogene, as PRMT6 overexpres-
sion promotes growth and prevents cellular senescence.
PRMT6 is overexpressed in several solid tumor types,
including breast, bladder, prostate, lung cancer, and lym-
phoma. Although PRMT6 overexpression was observed in
40% of lymphoma patients based on cDNA microarrays,
PRMT6 overexpression has not been reported in other he-
matologic malignancies at this time [5]. Whether the onco-
genic effects of PRMT6 are driven primarily by its roles in
impaired differentiation, increased cell cycle progression,
or decreased cellular senescence remains a critical question.PRMT7
PRMT7 is unique in that it is considered a type III arginine
methyltransferase, capable of forming only monomethylar-
ginine [64]. Mice lacking PRMT7 are viable but die5–10 days after birth because of skeletal abnormalities,
lower body mass, and decreased red blood cell counts [65].
PRMT7 has been implicated primarily in regulating the
DNA damage response. PRMT7 is associated with sensi-
tivity to DNA-damaging agents, such as topoisomerase in-
hibitors, whereas another study found that PRMT7 and
dimethylated H2AR3 and H4R3 are enriched at DNA repair
genes [66–68]. Knockdown of PRMT7 negatively regulates
the expression of multiple genes involved in DNA repair,
including ALKBH5, APEX2, POLD1, and POLD2 [69].
This study implicated the catalytic subunit of DNA poly-
merase (POLD1) as the main mediator of sensitivity to
DNA damage. Like PRMT5, PRMT7 methylates the Sm
spliceosome proteins and may play a role in mediating
snRNP assembly and RNA splicing [70]. Although alterna-
tive splicing regulated by PRMT5 has been found to modu-
late the DNA damage response, the role of PRMT7 in this
process has not been as extensively studied. Overall,
PRMT7 positively regulated genes in the DNA repair
pathway, and PRMT7 overexpression may desensitize can-
cer cells to DNA-damaging cancer therapies.
Like PRMT6, PRMT7 can antagonize the action of the
MLL methyltransferase complex. MLL4 is the major
mammalian H3K4 mono- and dimethyltransferase and is
critical for cellular differentiation. Increased MLL4-
catalyzed H3K4 methylation is associated with a decrease
in the PRMT7 methylation mark H4R3me1s. Knockdown
of PRMT7 enhanced the levels of H3K4me3, increased
the expression of MLL4 target genes, and promoted
neuronal differentiation [71]. PRMT7 also appears to be
important for B-cell differentiation, as it is highly expressed
in lymphoid tissues [72]. Conditional knockout of PRMT7
in the B-cell lineage resulted in impaired B-cell differenti-
ation and hyperplasia of the germinal center, whereas over-
expression of PRMT7 triggered an increase in Bcl6 in
germinal center-derived B-cell lines. Together, these studies
suggest that PRMT7 overexpression impairs lymphoid dif-
ferentiation and the DNA damage response; however,
PRMT7 has not been associated with the hematopoietic
malignancies to date.Conclusions and future directions
In summary, the protein arginine methyltransferases are
important regulators of HSPC self-renewal, differentiation,
and proliferation. The ability of PRMTs to modify both
transcription factors and histone substrates, via assembly
into various large multiprotein complexes, allows them to
control the activation and repression of the genes that regu-
late these biological processes. In fact, RUNX1 is a key
example of how multiple modifications catalyzed by
different PRMT family members can have opposing effects
on the same substrate. Like RUNX1, the MLL methyltrans-
ferase complex and SWI/SNF chromatin-remodeling com-
plex appear to receive multiple inputs from PRMTs.
440 S.M. Greenblatt et al./ Experimental Hematology 2016;44:435–441Finally, the role of multiple PRMTs in regulating alterna-
tive splicing may greatly impact the proliferation, differen-
tiation, and survival of HSPCs. Although these targets are
biologically important, it is likely that many additional tar-
gets for these enzymes remain to be discovered. Accumu-
lating evidence suggests that the PRMTs are important in
the pathogenesis of hematologic malignancies. Because of
the importance of AML1–ETO and MLL-fusion proteins
in leukemia development, their dependency on PRMTs
may be important for their function and could be exploited
therapeutically. Inhibitors targeting PRMT1, PRMT4,
PRMT5, and PRMT6 are already in development and
show great promise as novel therapeutics for the hemato-
logic malignancies.Acknowledgments
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